Comment on

• A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.

  Spinowitz B, Germain M, Benz R, Wolfson M, McGowan T, Tang KL, Kamin M; Epoetin Alfa Extended Dosing Study Group. Spinowitz B, et al. Clin J Am Soc Nephrol. 2008 Jul;3(4):1015-21. doi: 10.2215/CJN.05681207. Epub 2008 Apr 9. Clin J Am Soc Nephrol. 2008. PMID: 18400964 Free PMC article. Clinical Trial.
• Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.

  McGowan T, Vaccaro NM, Beaver JS, Massarella J, Wolfson M. McGowan T, et al. Clin J Am Soc Nephrol. 2008 Jul;3(4):1006-14. doi: 10.2215/CJN.05671207. Epub 2008 Apr 16. Clin J Am Soc Nephrol. 2008. PMID: 18417741 Free PMC article. Clinical Trial.
• Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.

  Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Kilpatrick RD, et al. Clin J Am Soc Nephrol. 2008 Jul;3(4):1077-83. doi: 10.2215/CJN.04601007. Epub 2008 Apr 16. Clin J Am Soc Nephrol. 2008. PMID: 18417744 Free PMC article. Clinical Trial.